We present here the results of a first-in-human, first-in-child trial for patients with
relapsed/refractory solid tumors using Celyvir, an advanced therapy medicine that combines …

Background Immune checkpoint inhibitors, which are a milestone in anti-cancer therapy,
have been applied in the treatment of multiple malignancies. Real-world data have …

Background Oncolytic viruses (OVs) are capable to inflame the tumor microenvironment
(TME) and elicit infiltrating tumor-specific T cell responses. However, OV treatment …

The search for an effective drug to treat oncological diseases, which have become the main
scourge of mankind, has generated a lot of methods for studying this affliction. It has also …

Effective depletion of immune suppressive regulatory T cells (Tregs) in the tumor
microenvironment without triggering systemic autoimmunity is an important strategy for …

Background Melanoma in people of Asian descent presents primarily in non-sun-exposed
areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed …

Abstract “Foreignization” of tumor cells via delivery of a non-self foreign antigen (Ag) into
tumors is an appealing strategy to initiate anti-tumor immunity that can facilitate tumor …

Besides the isolation and identification of major histocompatibility complex I-restricted
peptides from the surface of cancer cells, one of the challenges is eliciting an effective …

Oncolytic virotherapy can lead to systemic antitumor immunity, but the therapeutic potential
of oncolytic viruses in humans is limited due to their insufficient ability to overcome the …

Triple negative breast cancer (TNBC) does not respond to checkpoint blockade
immunotherapy as a result of immunosuppressive tumor microenvironment. To remodel the …